Marinus pharmaceuticals inc (MRNS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Expenses:
Research and development

15,004

12,512

11,572

10,010

8,872

8,087

9,148

7,232

3,927

3,344

2,642

2,817

3,573

4,413

4,840

7,258

5,494

6,061

3,472

3,915

5,468

2,167

1,569

2,805

2,149

1,008

1,326

General and administrative

3,850

2,960

2,327

2,502

3,667

2,187

2,073

2,338

2,187

1,593

1,571

1,691

1,812

1,518

1,529

1,586

1,604

1,436

1,378

1,255

1,447

1,388

868

458

516

313

313

Loss from operations

-18,854

-15,472

-13,899

-12,512

-12,539

-10,274

-11,221

-9,570

-6,114

-4,937

-4,213

-4,508

-5,385

-5,931

-6,369

-8,844

-7,098

-7,497

-4,850

-5,170

-6,915

-3,555

-2,437

-3,263

-2,665

-1,321

-1,640

Interest income

222

75

93

90

96

162

111

65

116

208

45

31

40

36

36

34

22

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-794

31

-428

-91

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

15

14

3

4

1

4

6

3

Interest expense

-

-

-

-

-

-

-

-

-

0

3

72

84

98

118

124

124

121

121

117

116

-

29

29

-

-

44

Other expense

-40

-11

-1

-1

-40

-

-

1

-1

-9

1

-3

-9

-21

-13

-15

-16

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7

-1

10

-

-

-

-2

-

-

Net loss

-18,700

-15,409

-13,800

-12,423

-12,483

-10,113

-11,110

-9,504

-5,999

-4,738

-4,170

-4,552

-5,438

-6,014

-6,464

-8,949

-7,216

-7,607

-4,963

-5,273

-7,007

-3,608

-1,668

-3,322

-2,235

-1,223

-1,681

Deemed divideds on convertible preferred stock

8,880

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

372

1,103

1,071

1,028

940

Net loss applicable to common shareholders

-27,552

-

-

-

-12,483

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,607

-2,040

-4,425

-3,306

-2,252

-2,621

Per share information:
Net loss per share of common stock—basic and diluted

-0.32

-0.25

-0.26

-0.24

-0.24

-0.24

-0.27

-0.24

-0.15

-0.18

-0.15

-0.21

-0.26

-0.31

-0.33

-0.46

-0.37

-0.45

-0.35

-0.37

-0.50

13.12

-0.22

-7.98

-7.09

-4.58

-5.66

Basic and diluted weighted average shares outstanding

86,661

60,520

52,543

52,522

52,465

42,405

40,407

40,395

40,373

22,930

28,666

21,985

20,580

19,509

19,509

19,509

19,464

19,097

12,289

14,223

14,068

14,140

9,449

554

466

492

463

Net loss

-18,700

-15,409

-13,800

-12,423

-12,483

-10,113

-11,110

-9,504

-5,999

-4,738

-4,170

-4,552

-5,438

-

-6,464

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities

28

-

1

-

2

25

42

38

-11

-

-18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-18,644

-15,412

-13,805

-12,423

-12,481

-10,088

-11,068

-9,466

-6,010

-

-4,188

-

-5,438

-

-6,464

-

-

-

-

-

-

-

-

-

-

-

-